CN114527282A - Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof - Google Patents
Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof Download PDFInfo
- Publication number
- CN114527282A CN114527282A CN202210150779.XA CN202210150779A CN114527282A CN 114527282 A CN114527282 A CN 114527282A CN 202210150779 A CN202210150779 A CN 202210150779A CN 114527282 A CN114527282 A CN 114527282A
- Authority
- CN
- China
- Prior art keywords
- detection
- sample
- saliva
- sampling
- nasal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 225
- 210000003296 saliva Anatomy 0.000 title claims abstract description 103
- 210000003928 nasal cavity Anatomy 0.000 title claims abstract description 77
- 238000005516 engineering process Methods 0.000 title claims abstract description 29
- 238000005070 sampling Methods 0.000 claims abstract description 146
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000003018 immunoassay Methods 0.000 claims abstract description 19
- 239000004005 microsphere Substances 0.000 claims abstract description 18
- 239000004816 latex Substances 0.000 claims abstract description 16
- 229920000126 latex Polymers 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims description 36
- 239000007791 liquid phase Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 13
- 239000007790 solid phase Substances 0.000 claims description 13
- 239000000020 Nitrocellulose Substances 0.000 claims description 12
- 229920001220 nitrocellulos Polymers 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000002033 PVDF binder Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 238000012827 research and development Methods 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract description 15
- 238000011068 loading method Methods 0.000 abstract description 3
- 239000011259 mixed solution Substances 0.000 abstract 3
- 239000000243 solution Substances 0.000 description 23
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 241000711573 Coronaviridae Species 0.000 description 12
- 101710141454 Nucleoprotein Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 6
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013504 emergency use authorization Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000012123 point-of-care testing Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920004933 Terylene® Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
The invention discloses a saliva and nasal cavity double-sample integrated sample adding detection technology, which comprises the steps of collecting a saliva sample through a saliva sampling structure, collecting a sample in a nasal cavity through the nasal cavity sampling structure, putting a sampling head of the nasal cavity sampling structure, which collects the nasal cavity sample, into the saliva sample to be mixed, preparing a mixed solution of the saliva sample and the nasal cavity sample, absorbing the mixed solution onto the sampling head of the nasal cavity sampling structure, directly inserting the sampling head into a detection sample collecting structure of a chromatography detection structure, directly loading the mixed solution onto a sample pad of a detection test strip, and starting and completing a detection process. The invention can be used for developing various rapid immunoassay products such as colloidal gold, fluorescence immunoassay, latex microspheres and the like, improves the detection efficiency, convenience and accuracy of immunoassay products, and has important clinical significance.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a detection technology for simultaneously sampling saliva and nasal cavity double samples and carrying out integrated sample adding detection and application thereof.
Background
The immunological detection technology is an experimental means for determining antigens, antibodies, immune cells, chemical components and the like by applying the immunological principle, and is widely applied to samples which are derived from human bodies and animal bodies and can be used for disease diagnosis and health detection and samples for environmental, pharmaceutical, food and industrial analysis. The common techniques include immunoturbidity technique, solid-phase enzyme immunochromatography assay, chemiluminescence assay, immunofluorescence labeling, quantum dot immunoassay, colloidal gold immunoassay, latex microsphere immunoassay, and spot immunoassay. High sensitivity, rapidness, convenience, miniaturization, full quantification and automation are development trends of clinical immunoassay technical products at present, and are perfected through various technical innovations and technical improvements. The point-of-care testing (POCT) is one branch developed most rapidly at present, chromatographic immunoassay is the most common testing method, and the products of the colloidal gold, the fluorescence lateral flow chromatography immunoassay and the latex microsphere immunoassay are widely used, but the adopted methods are generally sampling tests of a single sample. As is well known, the detection of nasal swab or anterior nasal swab is an important sampling mode for most respiratory infectious diseases at present, the virus load of respiratory system is high, but the defects are acceptability and convenience for collection and use, and the detection process requires an extracting solution to carry out pretreatment on a sample. Saliva is also used as one of the test samples, but the virus load is lower compared with the nasal swab, and the positive detection rate of the case is influenced. Therefore, the technology for sampling and detecting saliva and nasal cavity double samples is developed, so that the superposition of the virus load in two collected samples can be realized, the saliva is made into an effective solvent for use through the optimization treatment of a detection system, the rapid detection without an extracting solution is further realized, the more excellent accuracy, convenience, rapidity and operational simplicity of the use of a detection reagent are realized, the popularization and the use of clinical detection products are facilitated, the diagnosis and treatment quality is improved, and the important application value is realized.
Disclosure of Invention
Compared with the prior art, the invention has the characteristics of high detection sensitivity, convenience, rapidness, pollution prevention and the like, and improves the detection quality.
Aiming at the aim, the invention provides a technology for detecting the integrated sample adding of saliva and nasal cavity double samples, which comprises the following steps: collecting a saliva sample into a saliva collecting container by adopting a saliva sampling structure, extending a sampling head into a nasal cavity by adopting a nasal cavity sampling structure to collect a nasal cavity sample, directly placing the sampling head with the nasal cavity sample into the collected saliva sample, stirring and eluting to form a mixed liquid phase of the saliva sample and the nasal cavity sample, and soaking and absorbing the mixed liquid phase on the sampling head of the nasal cavity sampling structure, then the sampling head is directly inserted into a detection sample collecting structure arranged on the chromatography detection structure, the mixed liquid phase is directly loaded on a sample pad of the test strip which is in liquid flow communication with the test sample collection structure and flows through a marker binding pad, a solid-phase chromatography detection membrane and a water absorption pad, and reading the detection result by observing the amount of the indirectly captured marker on the solid-phase chromatography detection membrane, thereby completing the detection process.
In the above-mentioned detection technique, the saliva sampling structure is a container structure provided with an opening.
In the detection technology, the nasal cavity sampling structure is a rod-shaped structure with a sampling head made of water-absorbing materials arranged at the front end.
In the detection technology, the chromatography detection structure is a shell-shaped structure, a sampling head insertion opening is formed in the front end of the chromatography detection structure, an observation window is formed above the chromatography detection structure, the detection sample collection structure, the detection reagent strip placement bracket, the detection reagent strip positioned on the bracket and a liquid flow traffic opening between the detection sample collection structure and the detection reagent strip are arranged in the chromatography detection structure, and the detection reagent strip is sequentially provided with the sample pad, the marker combination pad, the solid-phase chromatography detection membrane and the water absorption pad from the sampling head insertion opening to the far end.
In the above-mentioned detection technology, the saliva sampling structure is composed of a funnel-shaped saliva collecting structure with a large top and a small bottom and a test tube-shaped saliva collecting container structure, and a detachable type split structure is arranged between the two.
In the above detection technology, the nasal cavity sampling structure is a plug-in structure in which the sampling head is directly connected with the sampling handle and extends out of the sampling handle.
In the detection technology, the solid-phase chromatography detection membrane is at least one of a nitrocellulose membrane, a polyvinylidene fluoride membrane, a nylon membrane and a DEAE cellulose membrane.
In the detection technology, the label in the label combining pad is at least one of colloidal metal, fluorescent label and latex microsphere.
The detection technology disclosed by the invention is applied to research and development of immunodetection products.
The sampling head is made of water-absorbing and water-insoluble materials, comprises natural and modified high-molecular super absorbent resin and artificially synthesized water-absorbing resin, and comprises starch series, cellulose series, other natural product series, polyvinyl acid salt series, polyvinyl alcohol series, polyoxyethylene series and the like, wherein part of polyvinyl alcohol series products have the characteristics of drying and hardening and water absorption softening, such as flocking, sponge, polyester fiber, terylene, cotton, various artificial fibers and the like.
The detection technology comprises an auxiliary detection liquid phase, wherein the auxiliary detection solution is a water quality buffer salt solution of a non-denaturant.
The detection reagent strip is a structure of a sample pad, a marker combination pad, a filtering membrane pad, a nitrocellulose membrane pad and a water absorption paper pad which are sequentially stuck on the PVC negative film and is placed in the detection card.
Due to the adoption of the technical scheme, the invention has the following advantages:
1. the invention adopts the saliva and nasal cavity double sample sampling and detecting technology, and the saliva and nasal cavity double samples are collected simultaneously during detection, so that the positive detection rate of cases can be obviously improved, the detection sensitivity of diseases is improved, and the method does not like the prior market which only can improve the sensitivity of a detection reagent and cannot change the pathogen carrying capacity of a sample to be detected. As is known, the detection of a nasal swab or a forenose swab is an important sampling mode for most of respiratory infectious diseases at present, the virus load of a respiratory system is high, but the defects are acceptability and convenience for collection and use, and an extracting solution is required for pretreatment of a sample in the detection process. Saliva is also one of the test samples, but the viral load is lower than that of a nasal swab, and the positive detection rate of a case is influenced. According to the invention, saliva and nasal cavity double-sample sampling is adopted, so that the superposition of virus loads in two collected samples can be realized, and simultaneously, saliva is made into an effective solvent for use through optimization treatment of a detection system, so that the rapid detection without an extracting solution is realized, and the more excellent accuracy, convenience, rapidity and simplicity in operation of the detection reagent are realized.
2. The nasal cavity sampling structure is used as a collecting structure of a nasal cavity object to be detected, and is a structure for adding samples when saliva and the nasal cavity object to be detected are detected, the saliva sampling structure is used as a collecting structure of the saliva object to be detected, the saliva collecting structure is used as a solvent liquid phase of the nasal cavity object to be detected and a flowing liquid phase for detecting the object to be detected, and creative multifunctional design is carried out on the sampling structure.
3. The saliva sampling structure is a funnel-shaped structure with a collecting pipe, so that saliva directly enters the collecting pipe after being spitted into the funnel, the operation is convenient, and the pollution is avoided.
4. The sampling structure comprises the sampling handle and the sampling head, wherein the sampling head has the double functions of sampling and detecting sample loading, and the sampling structure has the advantages of convenience in acquisition, sample transfer, sample loading safety and the like.
5. According to the invention, the sampling head containing the mixture of the saliva collection material and the nasal cavity collection material is directly inserted into the detection sample collection structure of the chromatography detection structure, the soaked and absorbed mixed liquid phase is directly loaded on the sample pad of the detection test strip which has liquid flow communication with the detection sample collection structure, and the detection reaction is started, so that not only is the sampling accuracy ensured, but also the structure and the detection function of the detection reagent strip are not influenced in the sampling process.
6. The invention adopts the detection test strip as a detection part, is suitable for various detection technologies which take lateral flow as main technical characteristics, such as colloidal gold, fluorescence immunoassay, latex microsphere immunoassay and the like, and expands the application range of the detection technology.
7. The invention is provided with the detection assisting liquid phase, can be used for samples with insufficient liquid phase, and improves the detection practicability.
8. The method has simple operation steps, is easy to realize household use or self-detection, is convenient to use, reduces the waste of raw materials, obviously improves the working efficiency, and is applied to various fields of professional and amateur detection.
Drawings
FIG. 1 is a schematic flow chart of the present invention;
FIG. 2 is a schematic view of a nasal sampling structure of the present invention;
FIG. 3 is a schematic diagram of a saliva sampling structure of the present invention;
FIG. 4 is a schematic view of a chromatographic detection structure of the present invention;
FIG. 5 is a schematic view of a sample collection structure for testing according to the present invention;
FIG. 6 is a clinical alignment study of nasal swab sampling antigen detection and PCR nucleic acid detection;
FIG. 7 is a clinical alignment study of saliva sampling antigen detection and PCR nucleic acid detection;
FIG. 8 is a clinical alignment study of double sample sampling antigen detection and PCR nucleic acid detection according to the present invention.
The figures are labeled as follows:
a nasal cavity sampling handle 1; a nasal cavity sampling fixing structure 2; a nasal cavity sampling head 3; a saliva collecting structure 4; a saliva collecting structure 5; detecting the connecting structure 6; a chromatographic detection structure 7; an observation window 8; a detection housing upper cover 9; a detection shell base 10 for detecting and connecting with a sampling head insertion opening 11; detecting the sample collection structure 12; the test strip 13.
Detailed Description
To further illustrate the technical means and effects of the present invention for achieving the predetermined purpose, the following embodiments are further described with reference to the accompanying drawings, but the present invention is not limited to the following description.
As shown in fig. 1, the technical process of the present invention includes 3 modules of a saliva sampling structure, a nasal cavity sampling structure and a chromatography detection structure, and the operation steps include: collecting saliva samples into a saliva collecting container by adopting a saliva sampling structure, extending a sampling head into a nasal cavity by adopting a nasal cavity sampling structure to collect nasal cavity samples, directly placing the sampling head with the nasal cavity samples into the collected saliva samples, stirring and eluting to form a mixed liquid phase of the saliva samples and the nasal cavity samples, and soaking and absorbing the mixed liquid phase on the sampling head of the nasal cavity sampling structure, then the sampling head is directly inserted into a detection sample collecting structure arranged in a chromatography detection structure, the soaked and absorbed mixed liquid phase is directly loaded on a sample pad of a detection test strip which has liquid flow communication with the detection sample collecting structure and flows through a marker combining pad, a solid-phase chromatography detection membrane and a water absorption pad, and reading the detection result by observing the condition that the marker on the solid-phase chromatography detection membrane is indirectly captured, thereby completing the detection process.
As shown in fig. 2, the nasal cavity sampling structure of the invention comprises a sampling handle 1, a sampling head fixing structure 2 and a sampling head 3, wherein the sampling head 3 is fixed on the sampling handle 1 through the sampling head fixing structure 2, and the sampling handle 1 is held by hand during operation to place the sampling head 3 in the front nasal cavity for sampling.
As shown in fig. 3, the saliva sampling structure of the invention can adopt a funnel-shaped saliva collecting structure 4, and is connected with a saliva collecting pipe 5 in a detachable manner downwards, when in use, saliva is spitted to the saliva collecting structure 4 through the oral cavity and flows into the saliva collecting pipe 5, then the sampling head 3 which is loaded with the nasal cavity sample and is used for sampling is inserted into the saliva collecting pipe 5, the saliva is stirred by attaching walls, a mixture of the nasal cavity sample and the saliva sample is formed and is soaked and absorbed on the sampling head 3, and the sampling process of integrating the two samples is completed.
As shown in fig. 4 and 5, the chromatography detection structure of the present invention has a nasal cavity sampling structure for detecting sample application, and includes a sampling handle 1, a fixing structure 2 and a sampling head 3, and a chromatography detection structure for sample detection, which includes a detection connection structure 6, a chromatography detection structure 7, an observation window 8, a detection housing upper cover 9, a detection housing base 10, a detection connection sampling head insertion opening 11, a detection sample collection structure 12 and a detection reagent strip 13.
Thus, in practical operation, when the detection technology is a colloidal gold immunoassay structure, the detection reagent strip 13 is a test strip prepared by a colloidal gold method, and a sample pad, a colloidal gold binding pad coated with a colloidal gold marker, a nitrocellulose membrane pad coated with a non-labeled capture reagent and a water absorption paper pad are sequentially adhered on a PVC support plate; when the detection technology is a fluorescence immunoassay structure, the detection reagent strip 13 is a test strip prepared by a fluorescence immunoassay method, and a sample pad, a fluorescent microsphere binding pad coated with a fluorescent marker, a nitrocellulose membrane pad coated with a non-marker capture reagent and a water absorption paper pad are sequentially adhered on a PVC (polyvinyl chloride) support plate; when the detection technology is a latex microsphere immunoassay structure, the detection reagent strip 13 is a test strip prepared by a latex microsphere immunoassay method, and a sample pad, a latex microsphere bonding pad coated with a latex microsphere marker, a nitrocellulose membrane pad coated with a non-labeled capture reagent and a water absorption paper pad are sequentially adhered on a PVC (polyvinyl chloride) supporting plate. When the saliva sampler is used, the saliva sampling structure, the nasal cavity sampling structure and the chromatography detection structure are taken out, and a saliva sample is collected into the saliva collecting pipe 5 through the saliva collecting structure 4 by adopting the saliva sampling structure; the hand-held sampling handle 1, stretch into nasal cavity collection nasal cavity sample with sampling head 3, the direct sampling head 3 that will gather the nasal cavity sample puts into the saliva sample of gathering, stir the elution, form the mixed liquid phase of saliva sample and nasal cavity sample, and make mixed liquid soak and absorb on sampling head 3, then connect sampling head 3 through detecting that sampling head inserted hole 11 disect insertion sets up in the detection sample collection structure 12 of chromatography detection structure, soaked absorptive mixed liquid phase is directly loaded to and has the sample pad of the detection test paper strip 13 of liquid flow traffic with detection sample collection structure 12, the mark bonding pad of flowing through, solid-phase chromatography detection membrane and the pad that absorbs water, through observing the condition that the last mark of solid-phase chromatography detection membrane is caught by the indirection, read the testing result, accomplish the testing process.
Experimental study of the invention: the following experiment is illustrative of the detection technique of the present invention and its effects, but is not intended to limit the present invention. The experimental methods used in the following experiments are all conventional methods unless otherwise specified. The materials, reagents and the like used are commercially available unless otherwise specified.
Experiment one: the invention relates to an immune colloidal gold method new coronavirus antigen rapid detection experiment:
firstly, preparing a detection reagent strip:
preparing a detection reagent strip by adopting a conventional immune colloidal gold detection technology and a double-antibody sandwich method, and preparing the detection reagent strip by adopting the detection technology to carry out a new coronavirus antigen detection experiment, wherein a colloidal gold label of a detection line T of the detection reagent strip indicates that an antibody is an anti-new coronavirus N protein monoclonal antibody of 10ug/ml, and colloidal gold particles with the particle size of 50nm are coated on a glass cellulose membrane colloidal gold combination pad; the capture antibody of the detection line T of the detection reagent strip is a 1.0mg/ml paired anti-new coronavirus N protein monoclonal antibody, and the capture antibody is coated on a nitrocellulose membrane; the capture antibody of the quality control line C of the detection reagent strip is a goat anti-mouse IgG polyclonal antibody of 1.0mg/ml, and the capture antibody is coated on a nitrocellulose membrane and used for capturing the colloidal gold labeled anti-new coronavirus N protein monoclonal antibody which is not captured specifically. And respectively sticking a water absorption paper membrane pad and a colloidal gold mark combined membrane pad at two ends of the nitrocellulose membrane printing membrane, and sticking a sample pad at one side of the combined membrane pad. And placing the adhered detection sheet on a strip cutting machine, and cutting into 3.5mm test strips.
Secondly, preparing a chromatography detection structure:
the upper cover, the base, the nasal cavity sampling structure and the saliva sampling structure of the chromatography detection structure are designed by Solidworks, samples are printed in 3D, a sponge sampling head is pasted on a sampling head fixing structure, a small-sized storage tube for experiments is used as a saliva sampling collecting tube, and a chromatography detection structure sample is prepared for experiment detection.
Third, experimental method and result:
during the experiment, the prepared detection reagent strip and the chromatography detection structure are assembled into a detection buckle, the assembled detection buckle is placed into an aluminum amber sealing bag with a drying agent, the sealing is carried out on a sealing machine, and a label is added. Preparing two solutions to be detected, 1) preparing recombinant new coronavirus antigen N protein solutions with different concentrations by using saliva (saliva) of a healthy person; 2) preparing 3 times of the concentration of the recombinant new coronavirus antigen N protein solution with different concentrations in the solution 1) by using non-inactivated virus preservation solution (UTM). Two methods are respectively adopted for detection, wherein the method I comprises the following steps: taking 150ul of solution 1), adding the solution into a test tube, taking a nasal cavity sampling structure, collecting a nasal cavity sample of a healthy person, inserting a sampling head into the solution 1), stirring and absorbing the solution 1), then inserting the sampling head into a detection buckle card through an insertion hole, standing for 20 minutes, observing a detection window, and reading a color development result on a test strip. The second method comprises the following steps: taking 100ul of healthy human saliva without N protein, adding the saliva into a test tube, taking a nasal cavity sampling structure, collecting a healthy human nasal cavity sample, taking 50ul of solution 2) to a sampling head after nasal cavity sampling, inserting the sampling head into blank healthy human saliva, stirring and absorbing the blank healthy human saliva solution, then inserting the sampling head into a detection buckle card through an insertion hole, standing for 20 minutes, observing a detection window, and reading a color development result on a test strip. The quality control line C of the test strip is colored, and the test line T is not colored and is negative; the quality control line C is colored, and the detection line T is also colored and is positive. As a result, positive reactions were observed in the antigen N protein solutions at final concentrations of 1.0, 0.1, 0.05 and 0.01ng/ml, and negative reactions were observed at concentrations of 0.001ng/ml or less.
Experiment two: the latex microsphere immunochromatography method for rapid detection of the new coronavirus antigen comprises the following steps:
firstly, preparing a detection reagent strip:
preparing a detection reagent strip by adopting a conventional latex microsphere immunochromatography double-antibody sandwich method, and preparing a detection kit by adopting the chromatography detection structure to perform a new coronavirus antigen detection experiment, wherein latex microspheres are biological red microspheres of 300nm, and a latex microsphere mark indication antibody of a detection line T of the detection reagent strip is an anti-new coronavirus N protein monoclonal antibody of 50ug/ml, and is coated on a glass cellulose membrane combination pad; the capture antibody of the detection line T of the detection reagent strip is a 1.0mg/ml paired anti-new coronavirus N protein monoclonal antibody, and the capture antibody is coated on a nitrocellulose membrane; the capture antibody of the quality control line C of the detection reagent strip is a goat anti-mouse IgG polyclonal antibody of 1.0mg/ml, and the capture antibody is coated on a nitrocellulose membrane and used for capturing latex microspheres marked with anti-new coronavirus N protein monoclonal antibodies which are not captured specifically. And respectively sticking a water absorption paper membrane pad and a latex microsphere mark combined membrane pad at two ends of the nitrocellulose membrane printing membrane, and sticking a sample pad at one side of the combined membrane pad. And placing the adhered detection sheet on a strip cutting machine, and cutting into 3.5mm test strips.
Secondly, preparing a chromatography detection structure:
prepared as in experiment one.
Third, experimental method and result:
during the experiment, the prepared detection reagent strip and the chromatography detection structure are assembled into a detection buckle, the assembled detection buckle is placed into an aluminum amber sealing bag with a drying agent, the sealing is carried out on a sealing machine, and a label is added. Preparing two solutions to be detected, namely 1) preparing recombinant new coronavirus antigen N protein solutions with different concentrations by using saliva (saliva) of a healthy person; 2) preparing 3 times of the concentration of the recombinant new coronavirus antigen N protein solution with different concentrations in the solution 1) by using non-inactivated virus preservation solution (UTM). Two methods are respectively adopted for detection, wherein the method I comprises the following steps: taking 150ul of solution 1), adding the solution into a test tube, taking a nasal cavity sampling structure, collecting a nasal cavity sample of a healthy person, inserting a sampling head into the solution 1), stirring and absorbing the solution 1), then inserting the sampling head into a detection buckle card through an insertion hole, standing for 20 minutes, observing a detection window, and reading a color development result on a test strip. The second method comprises the following steps: taking 100ul of healthy human saliva without N protein, adding the saliva into a test tube, taking a nasal cavity sampling structure, collecting a healthy human nasal cavity sample, taking 50ul of solution 2) to a sampling head after nasal cavity sampling, inserting the sampling head into blank healthy human saliva, stirring and absorbing the blank healthy human saliva solution, then inserting the sampling head into a detection buckle card through an insertion hole, standing for 20 minutes, observing a detection window, and reading a color development result on a test strip. The quality control line C of the test strip is colored, and the test line T is not colored and is negative; the quality control line C is colored, and the detection line T is also colored and is positive. As a result, positive reactions were observed in the antigen N protein solutions at concentrations of 1.0, 0.1, 0.05 and 0.01ng/ml, and negative reactions were observed at concentrations of 0.001ng/ml or less.
Experiment three: the influence of single-sample and double-sample integrated sampling on the clinical detection performance of the new coronavirus
Firstly, preparing a detection reagent strip:
the same procedure as in experiment two was followed.
Secondly, preparing a chromatographic detection structure by using the detection technology of the invention:
prepared as in experiment one.
Thirdly, nucleic acid detection reagent for control:
control detection material: the nucleic acid detection is carried out by RT-qPCR, the product adopts BGI new coronavirus nucleic acid real-time fluorescent RT-PCR kit (product number MFG 030010), FDA Emergency Use Authorization (EUA) is obtained 3 months in 2020, the packaging specification is 50 reactions/kits, the manufacturer is Huada gene, and the detection instruments are ABI 7500 fluorescent quantitative PCR detector, MGISP-960 high-flux automatic extraction and liquid treatment workstation and MGI Easy nucleic acid extraction kit (product number 1000020261).
Fourthly, experimental method and result:
the performance of the novel coronavirus antigen chromatographic detection structure prepared by the detection technology is evaluated and compared with the detection result of RT-qPCR.
1. Sample selection:
and selecting suspected cases infected by the new coronavirus and infected contact people, and dividing the sample into a positive group and a negative group according to the RT-qPCR nucleic acid detection result. And simultaneously detecting a nasal swab sample, a saliva sample and a mixed sample of the saliva and the nasal swab collection by using an RT-qPCR and antigen chromatography detection structure, and analyzing and comparing the two results.
2. Sample collection and processing
Sampling a sample for RT-qPCR detection by adopting a front nose sampling swab according to the specification requirement, and storing the sample in a non-inactivated UTM (UTM) storage solution; the sample for detecting the nasal swab antigen chromatography detection structure is sampled by adopting the nasal cavity sampling structure and is put into the non-inactivated UTM preservation solution for preservation; the saliva sampling structure is adopted to directly spit and collect saliva into a saliva collecting tube; the nasal cavity sampling structure is adopted to collect the nasal cavity sample, saliva is directly spitted into the saliva collecting tube and is collected into the saliva collecting tube, then the nasal cavity sampling structure is directly placed into the collected saliva, stirring and mixing are carried out, the saliva is soaked and absorbed onto the nasal cavity sampling head, and the nasal cavity sampling structure is used for standby detection.
Fifthly, result and analysis:
a total of 85 subjects were tested in alignment, 37 of them were clinical cases of new coronavirus infection and 48 were healthy population samples. The results were analyzed as follows:
as shown in fig. 6, 7 and 8, the detection results of 85 subjects showed that the positive coincidence rate of the sample collected by the nasal cavity sampling structure detected by the antigen chromatography detection structure was 91.2% and the negative coincidence rate was 100% compared with the RT-qPCR detection results of the anterior nasal sampling swab; the positive coincidence rate of the sample collected by the saliva sampling structure and detected by the antigen chromatography detection structure is 70.3 percent, and the negative coincidence rate is 100 percent; the double-sample detection technology is adopted, namely, saliva is directly spitted into a saliva collecting tube by taking a saliva sampling structure and is collected into the saliva collecting tube, then the nasal cavity sampling structure is directly placed into the collected saliva, stirring and mixing are carried out, the saliva is soaked and absorbed onto a nasal cavity sampling head, then the sampling head is directly inserted into a detection sample collecting structure in an antigen chromatography detection structure, detection is started, the result is observed, the positive coincidence rate of the detection is 100%, the negative coincidence rate is 100%, compared with two independent sampling detection technologies, the difference is obvious through statistical analysis, and p is less than 0.01. The detection technology of the invention can obviously improve the accuracy of the detection of the antigen chromatography detection structure, and simultaneously does not influence the detection specificity.
Claims (9)
1. A technology for detecting saliva and nasal cavity double-sample integrated sample adding comprises the following steps: collecting a saliva sample into a saliva collecting container by adopting a saliva sampling structure, extending a sampling head into a nasal cavity by adopting a nasal cavity sampling structure to collect a nasal cavity sample, directly placing the sampling head with the nasal cavity sample into the collected saliva sample, stirring and eluting to form a mixed liquid phase of the saliva sample and the nasal cavity sample, and soaking and absorbing the mixed liquid phase on the sampling head of the nasal cavity sampling structure, then the sampling head is directly inserted into a detection sample collecting structure arranged on the chromatography detection structure, the mixed liquid phase is directly loaded on a sample pad of the test strip which is in liquid flow communication with the test sample collection structure and flows through a marker binding pad, a solid-phase chromatography detection membrane and a water absorption pad, and reading the detection result by observing the amount of the indirectly captured marker on the solid-phase chromatography detection membrane, thereby completing the detection process.
2. The detection technique of claim 1, wherein: the saliva sampling structure is a container structure provided with an opening.
3. The detection technique of claim 1, wherein: the nasal cavity sampling structure is a rod-shaped structure of which the front end is provided with a sampling head made of water absorption materials.
4. The detection technique of claim 1, wherein: the chromatography detection structure is a shell-shaped structure, a sampling head insertion hole is formed in the front end of the chromatography detection structure, an observation window is formed above the chromatography detection structure, the chromatography detection structure is internally provided with the detection sample collection structure, the detection reagent strip placement bracket, the detection reagent strip positioned on the bracket and a liquid flow traffic opening between the detection sample collection structure and the detection reagent strip, wherein the detection reagent strip is sequentially arranged from the sampling head insertion hole to the far end, and the sample pad, the marker combination pad, the solid-phase chromatography detection membrane and the water absorption pad are sequentially arranged.
5. The detection technique of claim 1, wherein: the saliva sampling structure consists of a funnel-shaped saliva collecting structure with a large upper part and a small lower part and a test tube-shaped saliva collecting container structure, and a detachable split structure is arranged between the saliva collecting structure and the test tube-shaped saliva collecting container structure.
6. The detection technique of claim 1, wherein: the nasal cavity sampling structure is the sampling head with sampling handle lug connection and stretch out to the outside bayonet structure of sampling handle.
7. The detection technique of claim 1, wherein: the solid phase chromatography detection membrane is at least one of a nitrocellulose membrane, a polyvinylidene fluoride membrane, a nylon membrane and a DEAE cellulose membrane.
8. The detection technique of claim 1, wherein: the label in the label combining pad is at least one of colloidal metal, fluorescent label and latex microsphere.
9. Use of the assay technique of claim 1 in the research and development of immunoassay products.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210150779.XA CN114527282A (en) | 2022-02-18 | 2022-02-18 | Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof |
| PCT/CN2022/087800 WO2023155291A1 (en) | 2022-02-18 | 2022-04-20 | Test technique based on combined loading of saliva and nasal samples, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210150779.XA CN114527282A (en) | 2022-02-18 | 2022-02-18 | Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114527282A true CN114527282A (en) | 2022-05-24 |
Family
ID=81623186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210150779.XA Pending CN114527282A (en) | 2022-02-18 | 2022-02-18 | Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114527282A (en) |
| WO (1) | WO2023155291A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222543A1 (en) * | 2023-04-23 | 2024-10-31 | 闫丽霞 | Structure for detecting level of insulin in saliva and use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118542697A (en) * | 2024-05-13 | 2024-08-27 | 广州万方健医药有限公司 | The use of condoms used during intercourse for simultaneous collection and/or detection of male and female reproductive tract pathogens |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106168623B (en) * | 2016-05-12 | 2018-04-24 | 广州瑞辉生物科技股份有限公司 | Respiratory Tract Adenovirus IgA antibody test strip and its detection method |
| CN113249195A (en) * | 2020-02-12 | 2021-08-13 | 北京康华源科技发展有限公司 | Sample sampling device for detecting human pathogenic microorganisms and application thereof |
| JP2021188146A (en) * | 2020-05-26 | 2021-12-13 | 合同会社Ｈ．Ｕ．グループ中央研究所 | Guard tool and assembly method of guard tool |
| CN113740527A (en) * | 2021-09-08 | 2021-12-03 | 嘉兴康源科泰科技发展有限公司 | Sampling and detection integrated rapid detection structure and application thereof |
| CN114441755A (en) * | 2022-02-07 | 2022-05-06 | 嘉兴康源科泰科技发展有限公司 | Combined detection structure for double-sample sampling and integrated detection and application thereof |
-
2022
- 2022-02-18 CN CN202210150779.XA patent/CN114527282A/en active Pending
- 2022-04-20 WO PCT/CN2022/087800 patent/WO2023155291A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222543A1 (en) * | 2023-04-23 | 2024-10-31 | 闫丽霞 | Structure for detecting level of insulin in saliva and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023155291A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2443077C (en) | A "one-device" system for testing constituents in fluids | |
| JPH01229969A (en) | Improved immunological analysis of membrane support type | |
| US5250412A (en) | Swab device and method for collecting and analyzing a sample | |
| CN113740527A (en) | Sampling and detection integrated rapid detection structure and application thereof | |
| CN114527282A (en) | Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof | |
| US20050009200A1 (en) | Sanitary and compact fecal occult blood collector | |
| CN113848323A (en) | Column pushing type sampling detection integrated rapid detection structure and application thereof | |
| JP3757171B2 (en) | Extraction method of microbial antigen | |
| CN216117640U (en) | Sampling and detection integrated rapid detection structure | |
| CN114441755A (en) | Combined detection structure for double-sample sampling and integrated detection and application thereof | |
| CN114942328A (en) | Rapid detection structure for blood insulin level and application thereof | |
| CN216209190U (en) | Rapid detection structure for liquid phase sample sampling and detection | |
| CN201087838Y (en) | Myocardium calcium protein I color particle diagnosis test paper | |
| CN219810955U (en) | Saliva insulin level's short-term test structure | |
| CN219810954U (en) | Membrane chromatography detection structure of saliva insulin level | |
| CN116519957A (en) | Rapid detection structure for saliva insulin level and application thereof | |
| CN217688978U (en) | Quick detection structure of blood insulin level | |
| CN216209194U (en) | Quick detection structure of integration is detected in sampling of post pushing-type | |
| CN116449028A (en) | Membrane chromatography detection structure for saliva insulin level and application thereof | |
| CN219434845U (en) | Myocardial marker rapid detection kit for combined detection | |
| CN213398575U (en) | Novel test strip and kit for rapidly detecting coronavirus IgM/IgG | |
| JP4769171B2 (en) | Body fluid sample filtration separation apparatus and method | |
| CA2578313A1 (en) | Highly accurate rapid parallel immunoassay device | |
| CN114264816A (en) | Echinococcus antibody immunochromatographic test strip and detection card | |
| CN218180866U (en) | Immunochromatography detection structure capable of mediating release without combination pad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |